Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd is primarily engaged in the manufacturing and trading of pharmaceutical products and APIs. It has operations in India and caters to both domestic and international markets.[1]
- Market Cap ₹ 908 Cr.
- Current Price ₹ 344
- High / Low ₹ 515 / 270
- Stock P/E 37.1
- Book Value ₹ 64.4
- Dividend Yield 1.46 %
- ROCE 25.6 %
- ROE 19.9 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 35.2% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 40.0%
- Company's working capital requirements have reduced from 46.6 days to 35.6 days
Cons
- Promoter holding has decreased over last quarter: -0.39%
- Earnings include an other income of Rs.9.35 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
177 | 166 | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 221 | |
160 | 156 | 133 | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 202 | 195 | |
Operating Profit | 17 | 10 | 11 | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 35 | 26 |
OPM % | 9% | 6% | 7% | 6% | 8% | 4% | -9% | 6% | 5% | 10% | 12% | 15% | 12% |
0 | 0 | 0 | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | |
Interest | 4 | 5 | 5 | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
Depreciation | 3 | 3 | 3 | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 |
Profit before tax | 10 | 3 | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 33 |
Tax % | 26% | 28% | 16% | 30% | 20% | 18% | 1% | 20% | 16% | 22% | 29% | 23% | |
7 | 2 | 2 | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 25 | |
EPS in Rs | 2.85 | 0.70 | 0.81 | 0.45 | 1.24 | 4.53 | -4.41 | 2.76 | 3.00 | 6.51 | 7.20 | 10.20 | 9.36 |
Dividend Payout % | 18% | 72% | 62% | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% |
Compounded Sales Growth | |
---|---|
10 Years: | 4% |
5 Years: | 13% |
3 Years: | 14% |
TTM: | -5% |
Compounded Profit Growth | |
---|---|
10 Years: | 32% |
5 Years: | 35% |
3 Years: | 54% |
TTM: | 5% |
Stock Price CAGR | |
---|---|
10 Years: | 36% |
5 Years: | 69% |
3 Years: | 52% |
1 Year: | 0% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 13% |
3 Years: | 17% |
Last Year: | 20% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Reserves | 85 | 85 | 85 | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 156 |
35 | 33 | 36 | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | |
23 | 21 | 22 | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 31 | |
Total Liabilities | 156 | 153 | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 209 |
59 | 58 | 56 | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 10 | |
CWIP | 1 | 2 | 2 | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 1 |
96 | 92 | 98 | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 198 | |
Total Assets | 156 | 153 | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 209 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 12 | 8 | 4 | 9 | -3 | -2 | 31 | 11 | 28 | 7 | 47 | |
-5 | -3 | -1 | -0 | -2 | 41 | -3 | -1 | -11 | -2 | -26 | -58 | |
0 | -8 | -4 | -1 | -6 | -34 | -1 | -6 | -1 | -7 | -18 | -0 | |
Net Cash Flow | 3 | 0 | 2 | 2 | 1 | 5 | -6 | 24 | -0 | 19 | -36 | -11 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 93 | 115 | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 |
Inventory Days | 152 | 127 | 173 | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 81 |
Days Payable | 35 | 28 | 29 | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 64 |
Cash Conversion Cycle | 204 | 192 | 259 | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 49 |
Working Capital Days | 129 | 130 | 155 | 171 | 169 | 174 | 173 | 76 | 66 | 45 | 59 | 36 |
ROCE % | 11% | 6% | 6% | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 26% |
Documents
Announcements
- Submission Of Certificate From Practising Company Secretary Under Reg. 40(9) Of SEBI (LODR) Reg. 2015 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
2 Apr - In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 we are enclosing herewith a copy of the certificate received from M/s MCS …
-
Submission Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015
2 Apr - Compliance Certificate jointly executed by the authorized representative of our share transfer agent viz. MCS Share Transfer Agent Limited and the Compliance Officer of Jagsonpal …
- Closure of Trading Window 29 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
-
Financial Year 2010
from bse
Product Offerings
The company offers a range of pharmaceutical products under key therapeutic areas i.e. allergy management, immunity, cell protection, dentistry and ENT, women's healthcare, pregnancy care, and bone and joint care. [1]